State Street’s CAMP4 Therapeutics CAMP Stock Holding History

State Street’s Portfolio CAMP Stock Details CAMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.58M	Buy	362,300 +215,400	+147%	+$929K	﹤0.01%	3396
2026 Q1	$648K	Buy	146,900 +107,200	+270%	+$509K	﹤0.01%	3593
2025 Q4	$243K	Buy	39,700 +13,700	+53%	+$58.3K	﹤0.01%	3857
2025 Q3	$78K	Buy	+26,000	New	+$48.2K	﹤0.01%	4091
2025 Q2	–	Sell	-26,236	Closed	-$105K	–	4270
2025 Q1	$105K	Buy	26,236 +5,736	+28%	+$27.8K	﹤0.01%	3970
2024 Q4	$107K	Buy	+20,500	New	+$168K	﹤0.01%	3975

Other funds holding CAMP

Jupiter Topco New York $245B AUM

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

ACM

AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street's CAMP Position: Q2 2026 in Review

State Street increased its CAMP4 Therapeutics (CAMP) stake by 147% in Q2 2026, buying an estimated $929K and bringing the position to 362,300 shares worth $1.58M. The position accounts for ﹤0.01% of the portfolio, ranked #3396.

State Street first reported a position in CAMP in Q4 2024 and has held it in 6 quarters since. 61 funds tracked by Wall St. Rank hold CAMP as of Q2 2026.

State Street held 362,300 shares of CAMP4 Therapeutics worth $1.58M as of Q2 2026.
State Street bought 215,400 CAMP4 Therapeutics shares in Q2 2026, an estimated $929K.
CAMP4 Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3396 holding.
State Street first reported a position in CAMP4 Therapeutics in Q4 2024 and has held it in 6 quarters since.
61 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.